Teva is continuing to knock down one-by-one US state price fixing-claims, with the prospect of a criminal trial beginning in May next year.
Teva has agreed to settle price-fixing claims lodged by the state of Kentucky, the sixth such settlement the Israeli firm has reached in the US so far, with a $1.407m payment that will dismiss all claims against Teva and its affiliates once payment has been made.
The amount aligns with the framework Teva has followed to date, paying each state an amount proportional to its share...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
